Alnylam's Oxlumo Indicated For Treatment Of PH1 To Lower Uri

WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals Inc. (ALNY) said that the U.S. Food and Drug Administration approved a label expansion for Oxlumo (lumasiran), an RNAi therapeutic administered via

Related Keywords

Washington , United States , , European Medicines Agency , Drug Administration , Alnylam Pharmaceuticals Inc , Alnylam , Xlumo , Syndicated , Treatment , Tower , Urinary , Plasma , Oxalate , Levels ,